EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Single-blinded, stratified, dose ranging trial to assess pharmacokinetics and identify optimal dose of vitamin B12 in pregnancy in Tanzania

Omar Lweno, Victoria S Reynolds iD, Matthew D Barberio iD, Kevin C Klatt iD, Sabina Mugusi, Mathangi Gopalakrishnan, Zohra Lukmanji, Fadhlun M Alwy Al-Beity iD, Homa K Ahmadzia, Amrita Arcot, Kelly Gallagher, Leigh A Martin iD und 5 weitere

Gates Open Research · 2025

DOI: 10.12688/gatesopenres.15991.2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Gates Open Research, 2025. Verfasst von Omar Lweno und 16 weiteren Autor:innen. Beteiligte Einrichtung: Ifakara Health Institute, Dar es Salaam, Tanzania. Hauptthemen laut MEDLINE: Vitamin B 12, Dietary Supplements, Vitamin B 12 Deficiency. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gates Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Vitamin B12 is an essential cofactor for two enzymes that have critical functions in pregnancy, both for maternal health and fetal development. However, the optimal supplemental dosage and its correlation with vitamin B12 status during pregnancy remain inadequately understood due to limited data.

Methods

This is a single-blinded, stratified, dose-ranging trial of vitamin B12 supplementation that will be conducted at the Ifakara Health Institute Bagamoyo Clinical Trial Unit in Bagamoyo, Tanzania. We will enroll 40 pregnant participants (gestational age 25–28 weeks) and 10 non-pregnant participants, stratified based on baseline vitamin B12 status (sufficient and insufficient). Pregnant participants are sequentially assigned to one of three doses: 2.6, 10, and 50 µg for four weeks. At the highest dose, pregnant participants are randomized to receive 50 µg once a day (Q24H) or 25 µg twice a day (Q12H). The two lower doses (2.6 and 10 µg) are given Q24H. Non-pregnant participants will receive 2.6 µg Q24H. The trial includes a four week in-patient phase for daily assessment and controlled feeding, with pregnant participants assessed once postpartum. Primary endpoints include serum B12 concentrations, holotranscobalamin concentrations, and their ratio after four weeks of daily supplementation.

Discussion

This study aims to deepen our understanding of nutrient requirements in pregnancy by generating high-quality, high dimensional data. We will answer questions about how pre supplementation vitamin B12 status and dosage impact vitamin B12 saturable absorption and steady-state over the course of four weeks. Limitations include our inability to assess pharmacokinetic changes across gestation, the impact of vitamin B12 status or supplementation on pregnancy and fetal/newborn health, comparing vitamin B12 effects between pregnant and non-pregnant individuals above the recommended dietary allowance (2.6 µg), and comparing Q12H and Q24H dosing at 50 µg. This is the first controlled feeding study to be conducted in sub-Saharan Africa. Registration ClinicalTrials.gov ( NCT05426395 , 16/06/2022).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vitamin B 12Dietary SupplementsVitamin B 12 DeficiencyHumansFemalePregnancyTanzaniaSingle-Blind MethodAdultDose-Response Relationship, DrugYoung AdultRandomized Controlled Trials as Topic

Stichwörter der Autor:innen

Controlled FeedingPregnancyRandomized TrialTanzaniaVitamin B12 Deficiency

Substanzen

Vitamin B 12

Autor:innen und Institutionen

  • Ifakara Health Institute, Dar es Salaam, Tanzania.
  • Department of Global Health, The Milken Institute School of Public Health, The George Washington University, Washington, District of Columbia, 20052, USA.
  • Department of Exercise and Nutrition Science, The Milken Institute School of Public Health, The George Washington University, Washington, District of Columbia, 20052, USA.
  • Department of Nutritional Sciences and Toxicology, University of California Berkeley, Berkeley, California, 94720, USA.
  • Department of Clinical Pharmacology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
  • Center for Translational Medicine, School of Pharmacy, University of Maryland Baltimore, Baltimore, Maryland, 21201, USA.

ORCID-Profile: Victoria S Reynolds, Matthew D Barberio, Kevin C Klatt, Fadhlun M Alwy Al-Beity, Leigh A Martin, Ali Rahnavard, Honorati Masanja, Emily R Smith

Förderung

  • Gates Foundation

Zitieren

APA

Lweno, O., Reynolds, V. S., Barberio, M. D., Klatt, K. C., Mugusi, S., Gopalakrishnan, M., Lukmanji, Z., Al-Beity, F. M. A., Ahmadzia, H. K., Arcot, A., Gallagher, K., Martin, L. A., Rahnavard, A., Gernand, A. D., Langevin, B., Masanja, H., & Smith, E. R. (2025). Single-blinded, stratified, dose ranging trial to assess pharmacokinetics and identify optimal dose of vitamin B12 in pregnancy in Tanzania. Gates Open Research. https://doi.org/10.12688/gatesopenres.15991.2

Vancouver

Lweno O, Reynolds VS, Barberio MD, Klatt KC, Mugusi S, Gopalakrishnan M, et al. Single-blinded, stratified, dose ranging trial to assess pharmacokinetics and identify optimal dose of vitamin B12 in pregnancy in Tanzania. Gates Open Research. 2025. doi:10.12688/gatesopenres.15991.2

BibTeX
@article{Lweno2025,
  author = {Lweno, Omar and Reynolds, Victoria S and Barberio, Matthew D and Klatt, Kevin C and Mugusi, Sabina and Gopalakrishnan, Mathangi and Lukmanji, Zohra and Al-Beity, Fadhlun M Alwy and Ahmadzia, Homa K and Arcot, Amrita and Gallagher, Kelly and Martin, Leigh A and Rahnavard, Ali and Gernand, Alison D and Langevin, Brooke and Masanja, Honorati and Smith, Emily R},
  title = {Single-blinded, stratified, dose ranging trial to assess pharmacokinetics and identify optimal dose of vitamin B12 in pregnancy in Tanzania},
  journal = {Gates Open Research},
  year = {2025},
  doi = {10.12688/gatesopenres.15991.2}
}
Kostenlos starten →